CollPlant Biotechnologies - Likuiditas cepet CLGN

CollPlant Biotechnologies (CLGN) is a leader in regenerative therapy that developed a method for producing human collagen from plants. The price action on GURU.Markets reflects an asset with a liquidity ratio of 1.31. The company's revenues are based on the sale of bio-inks and partnership licenses, while its R&D pipeline focuses on 3D organ printing, including breast reconstruction, pushing the boundaries of modern restorative medicine.

The quick ratio measures a company's ability to instantaneously settle short-term obligations using cash and accounts receivable, completely excluding slow-moving inventories. By analyzing the current quick ratio, an investor assesses the financial stability of CollPlant Biotechnologies (CLGN), whose unique technology for synthesizing collagen in tobacco requires high operational flexibility to advance regenerative medicine.